DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
INCB-047986
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Arthritis, Rheumatoid
Tyrosine-protein kinase JAK1 inhibitor
INCB-047986
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEMOPORFIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Carcinoma, Non-Small-Cell Lung; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Klatskin Tumor; Nasopharyngeal Neoplasms; Neoplasms
Photosensitizer
TEMOPORFIN
×
Maximum Phase:
2
First Approval:
None
UNII:
FU21S769PF
Molecule Type:
Small molecule
Molecular Formula:
C44H32N4O4
Molecular Weight:
680.76
AlogP:
9.76
PSA:
138.28
HBD:
6.0
HBA:
#RotB:
4.0
Source:
TETRAHYDROPALMATINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
TETRAHYDROPALMATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3X69CO5I79
Molecule Type:
Small molecule
Molecular Formula:
C21H25NO4
Molecular Weight:
355.43
AlogP:
3.38
PSA:
40.16
HBD:
0.0
HBA:
#RotB:
4.0
Source:
FIALURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic; Herpes Simplex
Unknown
FIALURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
53T7IN77LC
Molecule Type:
Small molecule
Molecular Formula:
C9H10FIN2O5
Molecular Weight:
372.09
AlogP:
-1.27
PSA:
104.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
TIDEGLUSIB
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Child Development Disorders, Pervasive; Myotonic Dystrophy
Glycogen synthase kinase-3 beta inhibitor
TIDEGLUSIB
×
Maximum Phase:
2
First Approval:
None
UNII:
Q747Y6TT42
Molecule Type:
Small molecule
Molecular Formula:
C19H14N2O2S
Molecular Weight:
334.4
AlogP:
3.26
PSA:
44.0
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LAPACHONE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Neoplasms
Unknown
LAPACHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N4FA2QQ6A
Molecule Type:
Small molecule
Molecular Formula:
C15H14O3
Molecular Weight:
242.27
AlogP:
2.75
PSA:
43.37
HBD:
0.0
HBA:
#RotB:
0.0
Source:
MIVAVOTINIB CITRATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse
Tyrosine-protein kinase SYK inhibitor
MIVAVOTINIB CITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6ZJ8V3Q0H1
Molecule Type:
Small molecule
Molecular Formula:
C23H29FN6O8
Molecular Weight:
536.52
AlogP:
1.55
PSA:
97.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ACETIC ACID C-11
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Hepatocellular
Unknown
ACETIC ACID C-11
×
Maximum Phase:
2
First Approval:
None
UNII:
2A9OM7IPNW
Molecule Type:
Small molecule
Molecular Formula:
C2H4O2
Molecular Weight:
59.05
AlogP:
0.09
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
0.0
Source:
F901318
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
F901318
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUVN-G3031
2
Small molecule
Investigational
Unknown
Unknown
Cognitive Dysfunction; Narcolepsy
Histamine H3 receptor inverse agonist
SUVN-G3031
×
Maximum Phase:
2
First Approval:
None
UNII:
65V47O9NOP
Molecule Type:
Small molecule
Molecular Formula:
C21H31N3O3
Molecular Weight:
373.5
AlogP:
2.35
PSA:
54.04
HBD:
1.0
HBA:
#RotB:
6.0
Source:
VIPIVOTIDE TETRAXETAN GALLIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VIPIVOTIDE TETRAXETAN GALLIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C49H68GaN9O16
Molecular Weight:
1108.85
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
SOBLIDOTIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Lung Neoplasms; Sarcoma
Unknown
SOBLIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DQC51A0WQH
Molecule Type:
Small molecule
Molecular Formula:
C39H67N5O6
Molecular Weight:
701.99
AlogP:
3.99
PSA:
120.52
HBD:
2.0
HBA:
#RotB:
20.0
Source:
EVODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma, Open-Angle; Ocular Hypertension
Adenosine A2a receptor agonist
EVODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
HZ03U10J2Z
Molecule Type:
Small molecule
Molecular Formula:
C23H29N7O6
Molecular Weight:
499.53
AlogP:
-0.47
PSA:
177.95
HBD:
4.0
HBA:
#RotB:
4.0
Source:
SAF312
2
Small molecule
Investigational
Unknown
Unknown
Eye Pain; Pain; Urinary Bladder, Neurogenic
Vanilloid receptor inhibitor
SAF312
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QUINACRINE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Carcinoma, Renal Cell; Creutzfeldt-Jakob Syndrome; Prostatic Neoplasms, Castration-Resistant
Unknown
QUINACRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
H0C805XYDE
Molecule Type:
Small molecule
Molecular Formula:
C23H30ClN3O
Molecular Weight:
399.97
AlogP:
5.97
PSA:
37.39
HBD:
1.0
HBA:
#RotB:
9.0
Source:
DEFACTINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms
Focal adhesion kinase 1 inhibitor
DEFACTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
53O87HA2QU
Molecule Type:
Small molecule
Molecular Formula:
C20H21F3N8O3S
Molecular Weight:
510.5
AlogP:
2.4
PSA:
142.1
HBD:
3.0
HBA:
#RotB:
8.0
Source:
PF-06291874
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor antagonist
PF-06291874
×
Maximum Phase:
2
First Approval:
None
UNII:
CGY4I8F278
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-863233
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cell division cycle 7-related protein kinase inhibitor
BMS-863233
×
Maximum Phase:
2
First Approval:
None
UNII:
8QK62S7492
Molecule Type:
Small molecule
Molecular Formula:
C14H12ClN3O2
Molecular Weight:
289.72
AlogP:
2.75
PSA:
70.92
HBD:
2.0
HBA:
#RotB:
1.0
Source:
NBI-921352
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NBI-921352
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H25FN4O2S2
Molecular Weight:
460.6
AlogP:
4.1
PSA:
65.54
HBD:
1.0
HBA:
#RotB:
7.0
Source:
ATX08-001
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus; Neuralgia, Postherpetic
Peroxisome proliferator-activated receptor gamma modulator
ATX08-001
×
Maximum Phase:
2
First Approval:
None
UNII:
V5Q32BZX79
Molecule Type:
Small molecule
Molecular Formula:
C21H23Cl2N3O3S
Molecular Weight:
468.41
AlogP:
4.95
PSA:
81.06
HBD:
1.0
HBA:
#RotB:
8.0
Source:
AR9281
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Epoxide hydratase inhibitor
AR9281
×
Maximum Phase:
2
First Approval:
None
UNII:
4HA03Q8EZ9
Molecule Type:
Small molecule
Molecular Formula:
C18H29N3O2
Molecular Weight:
319.45
AlogP:
2.27
PSA:
61.44
HBD:
2.0
HBA:
#RotB:
2.0
Source:
PIBOSEROD
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation; Heart Failure
Serotonin 4 (5-HT4) receptor antagonist
PIBOSEROD
×
Maximum Phase:
2
First Approval:
None
UNII:
4UQ3S81B25
Molecule Type:
Small molecule
Molecular Formula:
C22H31N3O2
Molecular Weight:
369.51
AlogP:
3.67
PSA:
46.5
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PF-00217830
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D2 receptor partial agonist
PF-00217830
×
Maximum Phase:
2
First Approval:
None
UNII:
8BC08N1MS5
Molecule Type:
Small molecule
Molecular Formula:
C26H30N4O2
Molecular Weight:
430.55
AlogP:
4.1
PSA:
57.7
HBD:
1.0
HBA:
#RotB:
7.0
Source:
QUERCETIN-3'-O-PHOSPHATE
2
Small molecule
Investigational
Unknown
Unknown
Glucose Intolerance
Unknown
QUERCETIN-3'-O-PHOSPHATE
×
Maximum Phase:
2
First Approval:
None
UNII:
E2I4458LJN
Molecule Type:
Small molecule
Molecular Formula:
C15H11O10P
Molecular Weight:
382.22
AlogP:
1.75
PSA:
177.89
HBD:
6.0
HBA:
#RotB:
3.0
Source:
NAFITHROMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia, Bacterial
Unknown
NAFITHROMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
75F74Y2R70
Molecule Type:
Small molecule
Molecular Formula:
C42H62N6O11S
Molecular Weight:
859.06
AlogP:
4.12
PSA:
224.18
HBD:
2.0
HBA:
#RotB:
10.0
Source:
NAMODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic; Carcinoma, Hepatocellular; Non-alcoholic Fatty Liver Disease
Adenosine A3 receptor agonist
NAMODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
Z07JR07J6C
Molecule Type:
Small molecule
Molecular Formula:
C18H18ClIN6O4
Molecular Weight:
544.74
AlogP:
1.06
PSA:
134.42
HBD:
4.0
HBA:
#RotB:
5.0
Source:
ELISMETREP
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Hot Flashes
Transient receptor potential cation channel subfamily M member 8 inhibitor
ELISMETREP
×
Maximum Phase:
2
First Approval:
None
UNII:
KIB8V5UR7D
Molecule Type:
Small molecule
Molecular Formula:
C27H21F3N2O5S
Molecular Weight:
542.53
AlogP:
6.1
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
8.0
Source:
ANABASEINE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
ANABASEINE
×
Maximum Phase:
2
First Approval:
None
UNII:
DYE103K23I
Molecule Type:
Small molecule
Molecular Formula:
C10H12N2
Molecular Weight:
160.22
AlogP:
2.05
PSA:
25.25
HBD:
0.0
HBA:
#RotB:
1.0
Source:
UBENIMEX
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary; Lymphedema
Unknown
UBENIMEX
×
Maximum Phase:
2
First Approval:
None
UNII:
I0J33N5627
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O4
Molecular Weight:
308.38
AlogP:
0.53
PSA:
112.65
HBD:
4.0
HBA:
#RotB:
8.0
Source:
FIRTECAN PEGOL
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms; Breast Neoplasms
Unknown
FIRTECAN PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WC4978T687
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGB-BP-3
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
DNA binding agent
MGB-BP-3
×
Maximum Phase:
2
First Approval:
None
UNII:
532PWU9738
Molecule Type:
Small molecule
Molecular Formula:
C36H37N7O4
Molecular Weight:
631.74
AlogP:
4.65
PSA:
122.52
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TALAROZOLE
2
Small molecule
Investigational
Unknown
Unknown
Inflammation; Acne Vulgaris; Psoriasis
Cytochrome P450 26A1 inhibitor
TALAROZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKD9N5CJ6W
Molecule Type:
Small molecule
Molecular Formula:
C21H23N5S
Molecular Weight:
377.52
AlogP:
5.66
PSA:
55.63
HBD:
1.0
HBA:
#RotB:
7.0
Source:
NEOANDROGRAPHOLIDE
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis, Chronic Progressive; Colorectal Neoplasms
Unknown
NEOANDROGRAPHOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
XBY0Z806J2
Molecule Type:
Small molecule
Molecular Formula:
C26H40O8
Molecular Weight:
480.6
AlogP:
1.85
PSA:
125.68
HBD:
4.0
HBA:
#RotB:
7.0
Source:
GALICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator positive modulator
GALICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
J0IIT8QSQS
Molecule Type:
Small molecule
Molecular Formula:
C28H21F4NO7
Molecular Weight:
559.47
AlogP:
5.72
PSA:
103.32
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BREQUINAR
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Severe Acute Respiratory Syndrome
Unknown
BREQUINAR
×
Maximum Phase:
2
First Approval:
None
UNII:
5XL19F49H6
Molecule Type:
Small molecule
Molecular Formula:
C23H15F2NO2
Molecular Weight:
375.37
AlogP:
5.85
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
3.0
Source:
1
2
…
105
106
107
108
109
110
111
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA